Subcutaneous Daratumumab in High-Risk Smoldering Multiple Myeloma - Expert Perspectives on AQUILA Phase 3 Trial and FDA Approval
Explore the evolving treatment strategies for high-risk smoldering multiple myeloma, emphasizing early intervention and recent clinical advancements.

Featured Video

Malnutrition Poorly Impacts Survival With CCRT in Advanced Cervical Cancer


Cancer Vaccine Trial Receives FDA IND Clearance in Advanced Melanoma

New Career Center Video:   Learn how to build and strengthen your oncology referral network with expert insights from Tarita Thomas, MD, PhD, MBA, FACRO. Watch Increasing Your Oncology Referral Network now.
Videos
Trending

Optimizing Hypomethylating Therapy in Myelodysplastic Syndromes
This program focuses on optimizing the use of oral hypomethylating agents (HMAs) in myeloid malignancies, primarily high-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). A multidisciplinary panel of hematologists, transplant specialists, and an oncology nurse practitioner discusses real-world cases involving TP53-mutated MDS and proliferative CMML, both complicated by cytopenias, comorbidities, logistical challenges, and patient preferences. Panelists review evidence supporting oral decitabine/cedazuridine as a practical and clinically effective therapy comparable to intravenous HMAs. They also discuss transplant candidacy, timing, and the emerging role of combination therapies such as venetoclax with oral HMAs. Across the program, speakers emphasize individualized patient-centered care, balancing disease control with quality of life, treatment burden, telemedicine integration, and realistic expectations. The experts conclude that oral HMA therapy will lead to broader community-based treatment, greater patient autonomy, and future expansion of combination regimens and clinical trials.

Featured Video
Practical Implementation of Oral HMAs in MDS/CMML: Safety, Monitoring, and Coordination
Explore the differences between bispecific antibodies and CAR T-cell therapy, highlighting their unique benefits and administration processes.

Clinical Essentials
Quick Picks Read By QxMD


 

When endocrine therapy + CDK4/6 inhibitor fails, what next?
Education Alert
Expert-Driven, Patient-Focused: Mastering Personalized Care for HER2-Low Metastatic Breast Cancer
0.25 CPD
What's really the difference between HER2-negative and HER2-low disease? See how this distinction impacts real treatment decisions.
 

Sacituzumab Govitecan Combo Reduces Progression, Death By 35% in Metastatic TNBC

FDA Accepts NDA for Bezuclastinib Combo in Gastrointestinal Stromal Tumors

New Career Center Video:  
Learn how to build and strengthen your oncology referral network with expert insights from Tarita Thomas, MD, PhD, MBA, FACRO. Watch Increasing Your Oncology Referral Network now.

Videos Trending    

Learn strategies and diagnostic options with patient cases
Education Alert
The Clock Is Ticking: Diagnostic Strategies for Timely Sepsis Intervention
0.50 CME / CE / ABIM MOC
How can you overcome diagnostic uncertainty with rapid tests and evidence-based strategies for timely sepsis care?
 

Education Alert
Endocrine Therapies in ER-Positive/HER2-Negative MBC: Understanding Their Benefits and Limitations to Optimize Treatment Selection
0.50 CME / CE / ABIM MOC
Did you know that approximately 50% of breast cancer patients who have been exposed to an AI over time in the metastatic setting develop an ESR1 mutation?